AstraZeneca beats profit expectations, thanks to cancer drugs

Signals Inbox·July 28, 2026·Biopharma

AstraZeneca beat profit expectations as oncology sales jumped 15% in the second quarter. The bigger point is that its existing cancer drugs are growing fast enough to absorb fresh clinical setbacks and keep its $80 billion 2030 revenue target alive.

Q1What actually happened?

According to AstraZeneca’s official results, second-quarter revenue reached $15.4 billion and core earnings rose to $2.63 per share. That beat the roughly $2.48 analysts expected. The main driver was oncology, where revenue increased 15% at constant exchange rates.

Q2Which drugs are doing the heavy lifting?

AstraZeneca has built several large cancer franchises instead of depending on one medicine. Tagrisso remains a major lung cancer drug, Imfinzi keeps expanding across different tumors, and Enhertu has become an important breast cancer treatment. Together, these products give AstraZeneca several ways to keep growing even when an experimental drug fails.

Q3Why does the 15% oncology growth matter?

Because AstraZeneca’s total quarterly revenue grew only 5% at constant exchange rates. Cancer medicines are therefore growing about three times faster than the company as a whole. Oncology is not simply helping. It is carrying a large part of the growth story and covering weaker areas elsewhere in the portfolio.

Q4What problem is this earnings beat hiding?

AstraZeneca has recently suffered important clinical setbacks, including a failed late-stage study for Wainua in heart disease. Another experimental cancer treatment missed one of its main trial goals. Drug development is unpredictable, so the company needs today’s successful medicines to keep producing cash while it searches for the next wave of winners.

Q5How big is AstraZeneca’s long-term bet?

The company still expects annual revenue to reach $80 billion by 2030, up from about $59 billion in 2025. That means it needs to add roughly $21 billion in annual sales within five years. Strong cancer growth makes that target look more realistic, but existing blockbusters cannot do all of the work forever.

Q6So what should we watch next?

Watch whether oncology can maintain double-digit growth and whether AstraZeneca’s new medicines become meaningful sellers. The company expects more than 20 important late-stage trial results over the next 18 months. This quarter bought it time, but those trials will decide whether the $80 billion target rests on a broad new pipeline or mainly on today’s cancer blockbusters.